InvestSMART

Island Pharmaceuticals Limited (ASX: ILA) - Announcements

- Current share price for ILA : $0.365

ASX company news and announcements for Island Pharmaceuticals Limited (ILA) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Island Pharmaceuticals Limited (ILA) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Island Pharmaceuticals Limited (ILA), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Island Pharmaceuticals Limited (ILA)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$108 Change of Director's Interest Notice - DF 5 Nov 2025 9:07AM $0.430 $0.365 fallen by 15.12%
$108 Cleansing Notice 30 Oct 2025 9:11AM $0.395 $0.365 fallen by 7.59%
$108 Application for quotation of securities - ILA 30 Oct 2025 9:09AM $0.395 $0.365 fallen by 7.59%
$108 Quarterly Appendix 4C and Activities Report 30 Oct 2025 9:02AM $0.395 $0.365 fallen by 7.59%
$108 FDA confirms response timing for Galidesivir 22 Oct 2025 9:33AM $0.390 $0.365 fallen by 6.41%
$108 Cleansing Notice 17 Oct 2025 9:13AM $0.370 $0.365 fallen by 1.35%
$108 Application for quotation of securities - ILA 17 Oct 2025 9:10AM $0.370 $0.365 fallen by 1.35%
$108 Results of AGM 9 Oct 2025 1:24PM $0.410 $0.365 fallen by 10.98%
$108 Notification regarding unquoted securities - ILA 3 Oct 2025 8:46AM $0.445 $0.365 fallen by 17.98%
$108 US FDA Type C meeting briefing document submitted 29 Sep 2025 8:29AM $0.410 $0.365 fallen by 10.98%
$108 FDA Meeting request granted 19 Sep 2025 9:29AM $0.365 $0.365 fallen by 0%
$108 Investor webinar 18 Sep 2025 9:06AM $0.355 $0.365 risen by 2.82%
$108 Investor presentation - Galidesivir update 17 Sep 2025 9:53AM $0.295 $0.365 risen by 23.73%
$108 Cleansing Notice 9 Sep 2025 8:29AM $0.300 $0.365 risen by 21.67%
$108 Application for quotation of securities - ILA 9 Sep 2025 8:29AM $0.300 $0.365 risen by 21.67%
$108 Letter to Shareholders, Notice of AGM & Proxy Form 5 Sep 2025 9:44AM $0.270 $0.365 risen by 35.19%
$108 FDA meeting request lodged for Galidesivir 1 Sep 2025 8:45AM $0.220 $0.365 risen by 65.91%
$108 FDA meeting request lodged for Galidesivir 1 Sep 2025 8:45AM $0.220 $0.365 risen by 65.91%
$108 Annual Report to shareholders (incl auditor independence) 29 Aug 2025 10:09AM $0.215 $0.365 risen by 69.77%
$108 Appendix 4G and Corporate Governance Statement 29 Aug 2025 8:27AM $0.215 $0.365 risen by 69.77%
$108 Annual Report to shareholders 29 Aug 2025 8:25AM $0.215 $0.365 risen by 69.77%
$108 Preliminary Final Report 29 Aug 2025 8:22AM $0.215 $0.365 risen by 69.77%
$108 Preliminary Final Report 29 Aug 2025 8:22AM $0.215 $0.365 risen by 69.77%
$108 Change in substantial holding 15 Aug 2025 10:07AM $0.185 $0.365 risen by 97.30%
$108 Date of AGM & Closing Date for Director Nominations 14 Aug 2025 12:08PM $0.180 $0.365 risen by 102.78%

76 - 100 of 454 results

Page 4 of 19

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.